A Phase I/II, Open-label, Two Part Study of GSK3359609 in Combination With Tremelimumab in Patients With Selected, Advanced Solid Tumors
CT166

Background
- **GSK3359609** is an indolyl-1-carboxamide (ICOSI) agonist antibody, selected for its preclinical activity, activity against ICOS-expressing tumors.
- **Tremelimumab** is a monoclonal antibody against the cytotoxic T lymphocyte-associated antigen-4 (CTLA-4) receptor.
- Combination treatment of GSK3359609 and tremelimumab was evaluated in preclinical studies.

Methods

**Participants**
- Participants must have documented disease progression following one prior standard chemotherapy regimen.
- Participants must have measurable disease (WHO criteria).
- Participants may or may not have prior programmed death-ligand 1 (PD-L1) treatment.

**Exclusion Criteria**
- Autoimmune disease (current or history) or syndrome that required systemic treatment within the past 2 years.
- Adequate organ function.

**Study Design**
- Randomized 2:1:1:1 allocation to 4 arms in Part 1: 80 mg, 40 mg, 20 mg, and placebo.
- PK/PD cohort of 12 patients randomized to receive GSK3359609 only.
- Part 2: 120 patients randomized to receive GSK3359609 + tremelimumab or placebo + tremelimumab.

**End points**
- **Primary**
  - Objective response to GSK3359609 or placebo + tremelimumab.
- **Secondary**
  - Safety, tolerability, and PK/PD profiles of GSK3359609 in combination with tremelimumab (Part 1).
  - PK/PD profile of GSK3359609 in combination with tremelimumab (Part 2).
  - Safety, tolerability, and PK/PD profiles of placebo in combination with tremelimumab (Part 1).

**Dose escalation**
- **Part 1 (GSK3359609 alone)**
  - Dose escalation scheme: 8 mg, 24 mg, 80 mg, 240 mg.
  - Dose-limiting toxicity (DLT) criteria: 3/6 patients on a dose level.

**Part 2 (GSK3359609 + tremelimumab)**
- Dose escalation scheme: 8 mg, 32 mg, 64 mg, 128 mg.
- Dose-limiting toxicity (DLT) criteria: 3/6 patients on a dose level.

**Study Population**
- Tumor type: non-small cell lung cancer, melanoma, nasopharyngeal carcinoma, nasopharyngeal carcinoma.

**ClinicalTrials.gov identifier**: NCT03693612.

Acknowledgments
- The study was conducted by GSK and was supported by GlaxoSmithKline (GSK), MedImmune, and AstraZeneca.
- The authors thank the patients and the investigators for their participation in the study.
- The authors thank the study site staff for their contributions to the study.

Presented at the American Association for Cancer Research (AACR), Atlanta, GA, USA. March 29–April 3, 2019.